CEE VC SUMMIT 2025

25th of March 8:00 am CET

Aplagon raises €7M
February 3, 2025·2 min read

Joy Laoun

News Editor, Vestbee

Helsinki's biotech startup Aplagon raises €7M to advance its APAC Therapeutic technology

Helsinki-based biotech startup Aplagon has secured €7 million in funding to advance its APAC therapeutic for thrombo-inflammatory diseases into Phase 2A clinical trials. The investors include Fåhraeus Startup and Growth AB (FSG) and the European Innovation Council (EIC) Fund.

  • Founded in 2009 by Aki Prihti and Riitta Lassila, Aplagon is a clinical-stage biopharmaceutical company focused on developing innovative treatments for thrombo-inflammatory diseases.
  • The startup's lead therapy, APAC, is designed to address vascular injury through a unique triple-action approach—antiplatelet, anticoagulant, and anti-inflammatory effects.
  • APAC is designed for use in hospitals and can be administered locally or via IV infusion. The startup reports that over 40 people have received APAC so far, with no safety concerns, and early clinical results are promising.
  • The company aims to tackle critical health challenges posed by thrombo-inflammatory conditions, such as AVF maturation failure and chronic limb-threatening ischemia (CLTI), which can result in severe complications, including amputations.

Details of the deal

“Thrombo-inflammation is a key underlying driver for many cardiovascular diseases. At FSG we look for revolutionary innovations, and we found precisely that with Aplagon’s APAC approach to treat this clear unmet medical need,"  General Partner at FSG, Johanna Asklin, commented.

  • The fresh capital raised will primarily be used to fund Aplagon's Phase 2a clinical trial for APAC targeting peripheral arterial occlusive disease (PAOD) and chronic limb-threatening ischemia (CLTI), as well as to complete three ongoing clinical trials.

"We’re delighted to secure this fund-raising, and to bring on board FSG and EIC Fund as highly experienced VC investors from outside Finland. We have been making strong progress, and this financing enables us to complete the three international clinical trials we have been running with APAC, and to start a Phase 2a study in PAOD/CLTI," Explains Aki Prihti, CEO at Aplagon.

Deals#News#Finland

Subscribe to our newsletter
Join Vestbee
Join the leading matchmaking platform for startups, VC funds, angels, accelerators and corporates
Join Now